Background: Early diagnosis of renal cell carcinoma is extremely significant for the effective treatment of kidney cancer. The development of AS1411 aptamer modified MnMoS2 QDs provides a promising fluorescence/magnetic resonance (MR) dual-modal imaging probe for the precise diagnosis of renal clear cell carcinoma. Methods: In this work, Mn-MoS 2 QDs were synthesized through a simple "bottom-up" one-step hydrothermal method. AS1411 aptamer was modified on the Mn-MoS 2 QDs to improve the specificity to renal cell carcinoma. The characteristics of Mn-MoS 2 QDs were confirmed by transmission electronic microscopy (TEM), atomic force microscope (AFM), X-ray photoelectron spectrometer (XPS), photoluminescence (PL) emission spectra, etc. Cellular fluorescence labelling was investigated using the Mn-MoS 2 QDs and AS1411-Mn-MoS 2 QDs. The T 1 -weighted MR imaging was assessed by the in vitro MR cell imaging and in vivo MR imaging. Finally, the longterm toxicity of Mn-MoS 2 QDs was investigated by the hematology and histological analysis. 
Introduction
Cancer has been a major public concern and a serious threat to health across the world. It is estimated that a total of 18.1 million new cancer cases and 9.6 million cancer deaths will occur worldwide in 2018. 1 Kidney cancer accounted for 3.3%
among the new cases and the incidence has increased globally in recent years. Specially, renal cell carcinoma is the main type and occupies approximately 90-95% of all kidney neoplasm. Unfortunately, about 30% of the renal cell carcinoma patients showed metastatic disease upon its diagnosis, thus, aggravating the mortality of the renal cell carcinoma patients. 2 Therefore, early diagnosis for the cancer is extremely important to greatly increase the chances for effective treatment of renal cell carcinoma.
Recently, multimodal imaging has attracted tremendous attention as an effective diagnosis strategy for the early detection of cancer. 4 The integration of several imaging techniques allows precise and fast diagnosis by acquiring the comprehensive information of the tissues through the signals of the synergistic-multiplexed imaging, including fluorescence imaging, photoacoustic imaging (PA), magnetic resonance imaging (MRI), computed tomography imaging (CT), etc. [5] [6] [7] Among them, MRI has revealed many advantages in the non-invasive diagnosis by producing high 3D spatially resolved images of the tissues with a deep penetration. [5] [6] [7] [8] On the other hand, fluorescence imaging (FL) is highly sensitive, thus could be applied for qualitative or quantitative studies of biological behaviors in molecular or cellular levels, which could compensate for the disadvantages of MRI. 9 Therefore, the combination of FL and MRI would maximize their advantages and provide an effective approach for the localization of cancer. 7, 10 Normally, gadolinium (Gd) has been widely used as the contrast agent attributed to the excellent contrast effect in T 1 -weighted imaging. 11 However, as reported, the Gd contained contrast agents may cause a rare but extremely severe disease, nephrogenic fibrosis. 12 Therefore, a special contrast agent without Gd is also needed to address this issue. Fortunately, manganese (Mn) element could also produce similar contrast enhancement in T 1 -weighted imaging ascribed to its five unpaired 3d electrons. 13 On the other hand, Mn is also an essential element of physiological metabolism, and its homeostasis can be effectively regulated by the in vivo biological system, enabling its potential application in MRI. 14 However, as previous reports, the Mn element in its free form may cause apparent neurotoxicity in the mice and rat study. For example, the aqueous Mn(II) has been found to impart neurotoxicity with an LD 50 in mice of 0.3 mmol/kg injected intravenously and 1.0 mmol/kg injected intraperitoneally. Therefore, various approaches were used to tackle the problem associated with free Mn by preparing chelated manganese, hybrid manganese agents, macromolecular agents, and nanoparticle-based agents to mask the free manganese. 15 In recent years, quantum dots (QDs) have been studied for their size-dependent optical and electronic properties attributed to the bandgap widening when the dimensions of QDs are reduced below the exciton Bohr radius of the material. 16 To date, various quantum dots have been prepared as fluorescent probes, including graphene QDs, semiconductor QDs, carbon dots, polymer dots, etc. [16] [17] [18] However, most of these QDs exhibited strong cell toxicity and low stability, hindering their applications in the biomedical fields. Recently, metallic atoms were also employed to dope in the 2D MoS 2 nanomaterials to improve their properties. 25 Tan et al substituted Mn atoms into the MoS 2 nanosheet by supercritical hydrothermal reaction to create the intrinsic ferromagnetism. 26 Se atoms were doped into the MoS 2 nanosheet to enhance the catalytic performance by the increasing number of active sites and enhanced conductivity. 27 However, to date, to the best of our knowledge, the Mn-doped MoS 2 QDs have not been investigated for MR imaging and cell fluorescence imaging. Besides, aptamers are short single-stranded DNA or RNA oligonucleotides that can specifically and selectively bind to small molecular ligands or protein targets with high affinity. Moreover, aptamers are highly specific, relatively small in size, non-immunogenic and can be readily stabilized by chemical modifications to enable the expansion of their diagnostic and therapeutic ability. 28 Till date, aptamers have been used as therapeutic aptamers for macular degeneration, oncology, diabetes, inflammation and coagulation. Among these aptamers, AS1411, a 26-base guanine-rich oligonucleotide (GRO) with an unmodified (phosphodiester) DNA backbone, is the first aptamer in clinical trials for the treatment of human cancer. The AS1411 aptamer could recognize nucleolin and be internalized in a variety of cancer cells, such as renal, breast and other adenocarcinoma cell lines. 29 In this study, the AS1411 aptamer was used to improve the targeting ability of Mn-MoS 2 QDs to renal cell carcinoma. Herein, in this study, we propose a novel Mn-doped MoS 2 QDs (Mn-MoS 2 QDs) via a "bottom-up" one-step hydrothermal technique for MR imaging and cell fluorescence labelling of renal cell carcinoma. AS1411 aptamer was used to improve the targeting ability of Mn-MoS 2 QDs to renal cell carcinoma. 30 The composition and structure of Mn-MoS 2 QDs were investigated by transmission electronic microscopy (TEM), atomic force microscope (AFM) and X-ray photoelectron spectrometer (XPS). The optical properties were analyzed with the photoluminescence (PL) emission spectra. We investigated the potential of application in cell fluorescence imaging using the 
Characterization of Mn-MoS 2 QDs
The size, morphology and composition of Mn-MoS 2 QDs and AS1411-Mn-MoS 2 QDs were analyzed with a dynamic light scattering (DLS) analyzer (Zetasizer Nano ZS90, England), an atomic force microscope (AFM, SP13800, Japan) and a high-resolution transmission electron microscopic (HR-TEM, JEOL JEM200CX, Japan) with energy dispersive X-ray function (EDS). X-ray photoelectron spectrometry (XPS) spectra were obtained from X-ray photoelectron spectrometer (XPS, Thermo escalab250Xi, USA). The content of Mn in Mn-MoS 2 QDs was assessed by an inductively coupled plasma mass spectrometry (ICP-MS, Optima 5300DV, PerkinElmer, USA). The UV-vis absorption spectra and PL emission of Mn-MoS 2 QDs were measured by a UV-vis NIR spectrometer (UH4150 HITACH) and LS55 Fluorescence Spectrometer (PerkinElmer, America), respectively. The absorbance for MTT assay was determined by a microplate reader (Multiskon MK3, USA) at 490 nm.
In vitro Cell Cytotoxicity
Cell Culture The aforementioned cell lines were maintained in RPMI medium containing 10% (v/v) FBS and penicillin-streptomycin (100 μg/mL) and incubated at 37°C in a humidified 5% CO 2 atmosphere.
Cell Cytotoxicity Test
Cell cytotoxicity of Mn-MoS 2 QDs was determined via MTT method. 31 Briefly, the above-mentioned cells were seeded in 96-well plates for 24 hrs for cell attachment. Subsequently, Mn-MoS 2 QDs at various concentrations were added in each cell and co-incubated for another 24 hrs. Then, 10 μL MTT solution (5mg/mL) was added to each well with further incubation for 4 hrs. Afterwards, the MTT solution was removed and replaced with 100 μL DMSO to dissolve the formazan crystals. Finally, the absorbance was detected at 490 nm using a BioTek Epoch microplate reader (Multiskon MK3, USA).
Bioimaging and Cell Labelling
The 786-O and EA.hy926 cells were used to assess the ability of Mn-MoS 2 QDs as fluorescence cell labelling agent. Cells were seeded on sterile coverslips in a 6-well plate overnight for cell attachment. Then, the cells were incubated with MnMoS 2 QDs (2 mM) or AS1411-Mn-MoS 2 QDs (2 mM) for 2 hrs for cellular labelling. Subsequently, the cells were washed three times with PBS. Finally, the samples were observed using a fluorescence microscopy.
T 1 Relaxivity of Mn-MoS 2 QDs
The 
In vitro Enhanced MR Imaging
To assess the MR cellular imaging ability of Mn-MoS 2 QDs and AS1411-Mn-MoS 2 QDs, 786-O and EA.hy926 cells were inoculated on 6-well plates overnight at a density of 2×10 5 cells/well. Subsequently, the cells were co-incubated with Mn-MoS 2 QDs or AS1411-MnMoS 2 QDs at a concentration of 2 mM for 2 hrs to allow cellular uptake. Thereafter, the cells were washed thrice with cold PBS and trypsinized with EDTA-trypsin, then were resuspended in 300 μL 1% agarose gel. Finally, the MR imaging was conducted on the previous MR system. 
In vivo MR Imaging

In vivo Toxicity Analysis
In vivo toxicity test was performed on the healthy Kunming mice (female, 8 weeks) . The animals were randomly divided into two groups: Control and AS1411-Mn-MoS 2 QDs (200 μL 2mM Mn), each group containing six mice. The blood samples were collected on days 1, 7 and 21 for blood serum analysis. Then, the blood samples were centrifuged at 3000 rpm for 5 mins to obtain the serum for biochemistry analysis. 32 Simultaneously, the mice were sacrificed to harvest the major organs (heart, liver, spleen, kidney and lung). Afterwards, the organs were fixed with 10% formalin, sectioned and stained with hematoxylin and eosin (H&E). Finally, the histological samples were examined under an optical microscope.
Statistical Analysis SPSS 16.0 software (Chicago, IL) was used for statistical analysis. One-way ANOVA and Dunnett t-tests were used to compare the statistical significance between different groups. Quantitative data are presented as mean ± SD, p<0.05 was considered significant in all cases.
Results and Discussion
Synthesis and Characterization of MnMoS 2 QDs
In this study, Mn-MoS 2 QDs were synthesized via "bottomup" one-step hydrothermal method using manganese nitrate tetrahydrate, sodium molybdate, and glutathione as manganese, molybdenum and sulfur sources, respectively. As shown in Figure 1A , a typical spherical morphology was observed in the TEM image of Mn-MoS 2 QDs. Mn-MoS 2 QDs exhibited excellent crystal structure with noticeable lattice fringes (spacing=0.24 nm) showed in the highresolved TEM images (inset in Figure 1A ). The spacing was consistent with the typical lattice of the MoS 2 QDs, indicating that the doping of Mn induced no obvious change to the crystal structure of MoS 2 QDs. 21, 22, 24 Moreover, the Mn-MoS 2 QDs were well dispersed with a narrow size distribution and an average diameter of approximately 6.07 nm ( Figure 1B) . QDs was further assessed by ICP-MS, and was calculated to be 9.5 (wt %), which is sufficient for the T 1 -weighted MR imaging. Furthermore, AFM was conducted to investigate the thickness and morphology of Mn-MoS 2 QDs. As shown in the AFM image ( Figure 1C and D) , the thickness ranged from 0.6 to 1.2 nm, indicating the monolayer or bilayer structure of the as-prepared Mn-MoS 2 QDs. 24 The XPS analysis was also conducted to evaluate the chemical structure of Mn-MoS 2 QDs. As shown in highresolution Mo 3d spectrum in Figure 2B , two typical peaks were observed at 228.1 eV and 232.6 eV, which corresponded to the Mo 3d 3/2 and Mo 3d 5/2, respectively, indicating that the Mo element existed as 4+ oxidation state in Mn-MoS 2 QDs. The peaks at 163.4 eV and 169.7 eV belong to the S 2p 3/2 and S 2p 1/2 orbitals of divalent sulfide ions ( Figure 2C ). Furthermore, two characteristic peaks were observed at 640.8 eV and 642.4 eV, which correspond to the spin-orbit coupled Mn 2p 3/2 , suggesting that the valence state of Mn-MoS 2 QDs was divalent and tetravalent ( Figure 2A ). These results demonstrated the successful synthesis of Mn-MoS 2 QDs.
Optical Features of Mn-MoS 2 QDs
The optical property of the Mn-MoS 2 QDs was characterized by ultraviolet-visible spectroscopy (UV-vis). As shown in Figure 3A , the UV-vis spectra of Mn-MoS 2 QDs showed a shoulder peak located at 290 nm attributed to the blueshifted excitonic peaks. Typically, the excitonic peaks always blue shift with the formation of MoS 2 QDs. The UV-vis spectra result further confirmed the successful formation of Mn-MoS 2 QDs. The fluorescence spectra of the Mn-MoS 2 QDs were measured at various excitation wavelengths from 260 to 380 nm and shown in Figure 3C and D. The excitation at 290 nm induced a strong luminescence band with a maximum at 380 nm ( Figure 3B ). And the emission peak red-shifted from 380 to 435 nm within the excitation wavelength ranging from 260 to 380 nm. The excitation-dependent emission is consistent with the previous studies. The Mn-MoS 2 QDs aqueous were observed as pale pink under natural light, but revealed vivid blue luminescence under the UV light excitation (Figure 3A inset) . Furthermore, the quantum yield (QY) of Mn-MoS 2 QDs was assessed by comparing with the quinine sulfate standard, and was calculated to be 41.45% ( Figure S1 ). The QY value was much 
T 1 Relaxivity
To evaluate the possibility of using Mn-MoS 2 QDs as MRI contrast agents, the T 1 relaxation times of the QDs at various Mn concentrations were measured with a 3.0T MR system. The T 1 relaxation time decrease with the increase of the amounts of Mn-MoS 2 QDs. As shown in Figure 5B , MnMoS 2 QDs clearly exhibited bright signal enhancement in the T 1 -weighted MR imaging. Furthermore, the bright signal enhancement indicated a concentration-dependent relation with the prepared Mn-MoS 2 QDs, thus manifesting their potential application as a T 1 -weighted contrast agent ( Figure 5A ). The longitudinal relaxation rate (1/T 1 ), also known as relaxivity r 1 , was calculated to be 16.95 mM
, which was 4-fold of the commercial product Gd-DTPA (4.21 mM
, Figure S2 ). The high r 1 relaxivity value of Mn-MoS 2 QDs might be mainly ascribed to high concentration of metal ions exposed on the surface of nanoparticles which favored the longitudinal relaxation of the water proton to present a better contrast effect. Furthermore, as shown in Figure S3 , AS1411 conjugation did not induce significant change on the MRI contrast effect of Mn-MoS 2 QDs. These results indicated that the prepared Mn-MoS 2 QDs could be a potential contrast agent for MR imaging to enhance the relaxivity of the commercial Gd-DTPA.
In vitro Cytotoxicity of Mn-MoS 2 QDs
Although the prepared Mn-MoS 2 QDs exhibited excellent MR contrast and PL property in aqueous solution, it is of great significance to ensure good biocompatibility of the QDs to be applied in cell labelling and tracking in the biological system. At first, the cytotoxicity of Mn-MoS 2 QDs at various concentrations was assessed against 786-O renal carcinoma and EA.hy926 normal umbilical vein endothelial cells. As shown in Figure 4A , the viability of EA.hy926 normal umbilical vein endothelial cells remained above 85% flowing with the incubation of MnMoS 2 QDs even at a high concentration of 0.22 mM. In contrast, the Mn-MoS 2 QDs indicated obvious toxicity to the 786-O cancer cells under the same situation. To further investigate the different appearance between normal and cancer cells, Mn-MoS 2 QDs were co-incubated with MDA-MB-231 breast cancer, HO-8910 ovarian cancer and HK-2 renal tubular cells. As indicated in Figure 4B , similarly, Mn-MoS 2 QDs revealed low toxicity to HK-2 normal cells and concentration-dependent cytotoxicity to the MDA-MB-231 breast cancer and HO-8910 ovarian cancer cells. Normally, the tumor microenvironment and lysosome exhibited mildly acidic and H 2 O 2 -rich property compared with the normal tissues. As reported, the Mn contained QDs indicated noticeable anticancer effect by the production of oxygen with H 2 O 2 triggered by Mn contained QDs. 33 Therefore, in this study, the cancer cytotoxicity associated with Mn-MoS 2 QDs may also be attributed to the generation of singlet oxygen from H 2 O 2 
In vitro Cell Labelling
Encouraged by the excellent PL property of the as- 
In vivo MRI
The potential of A1411-Mn-MoS 2 QDs as a MRI contrast agent for in vivo cancer imaging was investigated using BALB/c nude mice with 786-O renal carcinoma. T 1 -weighted MRI scans were conducted prior to, and at various time points post-injection of Mn-MoS 2 QDs and AS1411-Mn-MoS 2 QDs. As shown in Figure 7A and B, compared with the pre-injected mice, the tumor exhibited contrast-enhanced regions 15-min post-injection following Figure 7C . The MR signal intensity values of AS1411-Mn-MoS 2 QDs were higher than the counterparts in all time points, which was consistent with the T 1 -mapping MR images. It further demonstrated the targeting ability of the QDs to the tumor benefit from the AS1411 aptamer. In addition, as shown in Figure 7D , high MR signal was also observed within 6 hrs post-injection in the gall bladder and liver. However, the signal in the liver and bladder became weaker, indicating that the clearance of the QDs was mainly completed by hepatobiliary system. Overall, the in vivo MRI suggested the potential applications of AS1411-Mn-MoS 2 QDs for renal carcinoma diagnosis.
In vivo Cytotoxicity of Mn-MoS 2 QDs
In vivo cytotoxicity studies of the Mn-MoS 2 QDs were investigated on the healthy Kunming mice for 21 days. The Mn-MoS 2 QDs were suspended in PBS and injected in the mice via tail vein with the saline injected mice as Figure 8A , the hematological factors did not exhibit obvious difference between the control and Mn-MoS 2 QDs injected groups.
Only the WBC and RBC values showed slight decrease in the Mn-MoS 2 QDs injected mice compared with the control. However, all the hematological values including WBC still maintained within the normal range, indicating no acute toxicity. Serum biochemistry analysis was also performed to assess the potential toxicity of the MnMoS 2 QDs on mice. 33 As shown in Figure 8A , the blood urea nitrogen (BUN) maintained normal level, indicating the good condition of the kidney. Otherwise, the damage to the renal function may induce the increase of urea nitrogen in the blood. Furthermore, the hepatic function markers -albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total protein (TP) revealed a slight discrepancy in 1 day, but returned to the normal level in 7 and 21 days. However, all the hepatic indicators maintained within the normal ranges, demonstrating that Mn-MoS 2 QDs may affect the hepatic function in the short time after administration but without liver injury in a long term. Histological analysis for the major organs (heart, liver spleen, lung, kidney) was also performed to identify the effect of Mn-MoS 2 QDs to various tissues. As shown in Figure 8B , there was no obvious inflammation or damage lesions observed in major organs after 21-day injection of Mn-MoS 2 QDs. The H&E images exhibited similar morphology in the different organs compared with the control groups. These results suggested the low toxicity of the Mn-MoS 2 QDs in the animal body, unlocking their potential in biomedical applications.
Conclusions
A novel AS1411-Mn-MoS 2 nanoprobe was successfully synthesized via bottom-up one-step hydrothermal technique for targeted MR and fluorescence imaging of renal clear cell carcinoma. The as-prepared AS1411-Mn-MoS 2 QDs exhibited excellent aqueous property, intense luminescence, low toxicity and high quantum yield. Owing to the strong absorption and emission in the visible region, AS1411-Mn-MoS 2 QDs were successfully applied in cell labelling for renal cell carcinoma. Besides, AS1411-MnMoS 2 QDs also revealed wonderful targeted MR contrast behavior for the renal carcinoma in the in vitro and in vivo MR tests compared with the clinical Gd-DTPA. Therefore, the experimental results demonstrate that the AS1411-MnMoS 2 QDs could be used as a nanoprobe for the specific recognization of renal clear cell carcinoma.
